Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.
What is known and Objective: Preladenant (SCH420814, MK-3814) is a highly selective orally bioavailable non-methylxanthine adenosine 2A (A2A) receptor antagonist under investigation for the treatment for Parkinson's disease. This study evaluated the safety, tolerability and pharmacokinetics of prela...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 37; no. 5; pp. 578 - 588 |
|---|---|
| Autores principales: | , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Wiley-Blackwell
Oct2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |